Comparison
While Retatrutide is an investigational agent that produces very large body-weight reductions in early trials by simultaneously engaging GLP-1R, GIPR, and GCGR to enhance satiety, energy expenditure, and glycemic control2575, Thymosin Alpha-1 is clinically used in some countries as an immunomodulator for chronic hepatitis B/C and as an adjuvant in cancer therapy, enhancing cell-mediated immunity41487.
While Retatrutide works as a triple incretin agonist peptide derived from a GIP backbone and engineered to activate GLP-1, GIP, and glucagon receptors, with non-natural residues and fatty-acid conjugation that confer long half-life and balanced multi-receptor signaling256575, Thymosin Alpha-1 is a 28-amino-acid thymic peptide fragment of prothymosin alpha that activates dendritic cells and T cells primarily via TLR9/MyD88/NF-κB signaling, enhancing Th1 responses and NK-cell cytotoxicity414.
Retatrutide is 39 amino acids long, whereas Thymosin Alpha-1 is shorter as it has a length of 28 amino acids. Retatrutide is made up of a sequence of sequence data not available in the current dataset. Thymosin Alpha-1 is made up of a sequence of Serine, Aspartic acid, Alanine, Alanine, Valine, Aspartic acid, Threonine, Serine, Serine, Glutamic acid, Isoleucine, Threonine, Threonine, Lysine, Aspartic acid, Leucine, Lysine, Glutamic acid, Lysine, Lysine, Glutamic acid, Valine, Valine, Glutamic acid, Glutamic acid, Alanine, Glutamic acid, Asparagine.
Retatrutide
Not assigned in the current dataset.
Thymosin Alpha-1
PTMA